EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Locally Advanced or Metastatic Breast Cancer

Suparna Wedam iD, Preeti Narayan iD, Haley Gittleman iD, Joyce Cheng, Vishal Bhatnagar iD, Hairat Sabit, Lauren S L Price iD, Nam Atiqur Rahman, Haw-Jyh Chiu, Nikolett Biel, Tiffany Ricks, Mallorie Fiero und 6 weitere

Journal of Clinical Oncology · 2025-10 · 43 (28) · 3123-3131

DOI: 10.1200/jco-25-00663 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2025-10. Verfasst von Suparna Wedam und 17 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Class I Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The US Food and Drug Administration (FDA) approved inavolisib with palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA -mutated, hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative, locally advanced or metastatic breast cancer (MBC), as detected by an FDA-approved test, FoundationOne Liquid CDx assay, after recurrence on or after completing adjuvant endocrine therapy. PATIENTS AND METHODS Approval was based on INAVO120, a randomized, double-blind, placebo-controlled trial in 325 patients with endocrine-resistant, PIK3CA -mutated, hormone receptor–positive, HER2-negative, locally advanced or MBC. Patients were randomly assigned (1:1) to either inavolisib (n = 161) or placebo (n = 164) in combination with palbociclib and fulvestrant. RESULTS INAVO120 met its primary end point of progression-free survival (PFS) by investigator assessment, with a median PFS of 15.0 months for inavolisib + palbociclib + fulvestrant versus 7.3 months for placebo + palbociclib + fulvestrant (hazard ratio [HR], 0.43 [95% CI, 0.32 to 0.59]; P < .0001). The objective response rate was 58% (95% CI, 50 to 66) versus 25% (95% CI, 19 to 32). The median duration of response was 18.4 months (95% CI, 10.4 to 22.2) versus 9.6 months (95% CI, 7.4 to 16.6). Interim analysis of overall survival did not reach statistical significance but was supportive of the overall benefit-risk assessment with a HR of 0.64 (95% CI, 0.43 to 0.97). Consistent with the PI3Kα inhibitor class, common adverse reactions noted with inavolisib included hyperglycemia, stomatitis, diarrhea, and rash. CONCLUSION The approval of inavolisib with palbociclib plus fulvestrant was based on a statistically significant and clinically meaningful improvement in PFS observed in the INAVO120 trial. Before this approval, there were no specific therapies approved by the FDA for the first-line treatment of patients with endocrine-resistant, hormone receptor–positive advanced or MBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsClass I Phosphatidylinositol 3-KinasesHumansFulvestrantPiperazinesPyridinesFemaleErb-b2 Receptor Tyrosine KinasesUnited States Food and Drug AdministrationMiddle AgedDouble-Blind MethodReceptors, EstrogenDrug ApprovalDrug Resistance, NeoplasmAgedAdultReceptors, ProgesteroneUnited StatesMutationAged, 80 and overProgression-Free SurvivalNeoplasm Metastasis

Substanzen

FulvestrantPiperazinesPyridinesErb-b2 Receptor Tyrosine KinasesClass I Phosphatidylinositol 3-KinasesReceptors, EstrogenReceptors, ProgesteroneImidazolesOxazolespalbociclib

Autor:innen und Institutionen

  • Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD.
  • Oncology Center of Excellence (OCE), US Food and Drug Administration, Silver Spring, MD.
  • Paradigm Health, Columbus, OH.

ORCID-Profile: Suparna Wedam, Preeti Narayan, Haley Gittleman, Vishal Bhatnagar, Lauren S L Price, Shenghui Tang, William Pierce, Richard Pazdur, Laleh Amiri-Kordestani

Zitieren

APA

Wedam, S., Narayan, P., Gittleman, H., Cheng, J., Bhatnagar, V., Sabit, H., Price, L. S. L., Rahman, N. A., Chiu, H. J., Biel, N., Ricks, T., Fiero, M., Tang, S., Osgood, C., Pierce, W., Pazdur, R., Kluetz, P. G., & Amiri-Kordestani, L. (2025). US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Locally Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology, 43(28), 3123-3131. https://doi.org/10.1200/jco-25-00663

Vancouver

Wedam S, Narayan P, Gittleman H, Cheng J, Bhatnagar V, Sabit H, et al. US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Locally Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology. 2025;43(28):3123-3131. doi:10.1200/jco-25-00663

BibTeX
@article{Wedam2025,
  author = {Wedam, Suparna and Narayan, Preeti and Gittleman, Haley and Cheng, Joyce and Bhatnagar, Vishal and Sabit, Hairat and Price, Lauren S L and Rahman, Nam Atiqur and Chiu, Haw-Jyh and Biel, Nikolett and Ricks, Tiffany and Fiero, Mallorie and Tang, Shenghui and Osgood, Christy and Pierce, William and Pazdur, Richard and Kluetz, Paul G and Amiri-Kordestani, Laleh},
  title = {US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Locally Advanced or Metastatic Breast Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {28},
  pages = {3123--3131},
  doi = {10.1200/jco-25-00663}
}
Kostenlos starten →